



WHAT IS CLAIMED IS:

1. A compound having structural Formula ~~(II)~~(+):



or a pharmaceutically acceptable salt thereof, wherein:

~~X¹ is CR⁸ or N;~~

X² is CR⁹ or N;

X³ is CR¹⁰ or N;

n1, n2, ~~n3~~, n3.2, n3.3, n4, ~~n5~~, ~~n6~~, n7, ~~n8~~, n9, n10, and n44 are independently an integer from 0 to 4;

m1, m2, ~~m3~~, m3.2, m3.3, m4, ~~m5~~, ~~m6~~, m7, ~~m8~~, m9, m10, v1, v2, ~~v3~~, v3.2, v3.3, v4, ~~v5~~, ~~v6~~, v7, ~~v8~~, v9, v10, and v44 are independently 1 or 2;

~~z1 is an integer from 0 to 5;~~

~~z2 is an integer from 0 to 4;~~

~~z3 is an integer from 0 to 11;~~

z4 is an integer from 0 to 2;

L⁷ is a bond, -O-, -S-, -NR^{7.2B}-, -C(O)-, -C(O)O-, -S(O)-, -S(O)₂-, substituted or unsubstituted alkylene, substituted or unsubstituted heteroalkylene, substituted or unsubstituted cycloalkylene, substituted or unsubstituted heterocycloalkylene, substituted or unsubstituted arylene, or substituted or unsubstituted heteroarylene;

R¹ is hydrogen, halogen, -CX^{1.1}₃, -CHX^{1.1}₂, -CH₂X^{1.1}, -CN, -N₃, -SO_{n1}R^{1A}, -SO_{v1}NR^{1B}R^{1C}, -NHN^{1B}R^{1C}, -ONR^{1B}R^{1C}, -NHC(O)NHN^{1B}R^{1C}, -NHC(O)NR^{1B}R^{1C}, -N(O)_{m1}, -NR^{1B}R^{1C}, -C(O)R^{1D}, -C(O)OR^{1D}, -C(O)NR^{1B}R^{1C}, -OR^{1A}, -NR^{1B}SO₂R^{1A}, -NR^{1B}C(O)R^{1D}, -NR^{1B}C(O)OR^{1D}, -NR^{1B}OR^{1D}, -OCX^{1.1}₃, -OCHX^{1.1}₂, -OCH₂X^{1.1}, substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted cycloalkyl,

substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl;

R^2 is hydrogen, halogen, $-CX^{2.1}_3$, $-CHX^{2.1}_2$, $-CH_2X^{2.1}$, $-CN$, $-N_3$, $-SO_{n2}R^{2A}$, $-SO_{v2}NR^{2B}R^{2C}$, $-NHN R^{2B}R^{2C}$, $-ONR^{2B}R^{2C}$, $-NHC(O)NHN R^{2B}R^{2C}$, $-NHC(O)NR^{2B}R^{2C}$, $-N(O)_{m2}$, $-NR^{2B}R^{2C}$, $-C(O)R^{2D}$, $-C(O)OR^{2D}$, $-C(O)NR^{2B}R^{2C}$, $-OR^{2A}$, $-NR^{2B}SO_2R^{2A}$, $-NR^{2B}C(O)R^{2D}$, $-NR^{2B}C(O)OR^{2D}$, $-NR^{2B}OR^{2D}$, $-OCX^{2.1}_3$, $-OCHX^{2.1}_2$, $-OCH_2X^{2.1}$, substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl;

~~R^3 is independently halogen, $-CX^{3.1}_3$, $-CHX^{3.1}_2$, $-CH_2X^{3.1}$, $-CN$, $-N_3$, $-SO_{n3}R^{3A}$, $-SO_{v3}NR^{3B}R^{3C}$, $-NHN R^{3B}R^{3C}$, $-ONR^{3B}R^{3C}$, $-NHC(O)NHN R^{3B}R^{3C}$, $-NHC(O)NR^{3B}R^{3C}$, $-N(O)_{m3}$, $-NR^{3B}R^{3C}$, $-C(O)R^{3D}$, $-C(O)OR^{3D}$, $-C(O)NR^{3B}R^{3C}$, $-OR^{3A}$, $-NR^{3B}SO_2R^{3A}$, $-NR^{3B}C(O)R^{3D}$, $-NR^{3B}C(O)OR^{3D}$, $-NR^{3B}OR^{3D}$, $-OCX^{3.1}_3$, $-OCHX^{3.1}_2$, $-OCH_2X^{3.1}$, substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted aryl or substituted or unsubstituted heteroaryl;~~

$R^{3.2}$ and $R^{3.3}$ are independently halogen;

R^4 is hydrogen, halogen, $-CX^{4.1}_3$, $-CHX^{4.1}_2$, $-CH_2X^{4.1}$, $-CN$, $-N_3$, $-SO_{n4}R^{4A}$, $-SO_{v4}NR^{4B}R^{4C}$, $-NHN R^{4B}R^{4C}$, $-ONR^{4B}R^{4C}$, $-NHC(O)NHN R^{4B}R^{4C}$, $-NHC(O)NR^{4B}R^{4C}$, $-N(O)_{m4}$, $-NR^{4B}R^{4C}$, $-C(O)R^{4D}$, $-C(O)OR^{4D}$, $-C(O)NR^{4B}R^{4C}$, $-OR^{4A}$, $-NR^{4B}SO_2R^{4A}$, $-NR^{4B}C(O)R^{4D}$, $-NR^{4B}C(O)OR^{4D}$, $-NR^{4B}OR^{4D}$, $-OCX^{4.1}_3$, $-OCHX^{4.1}_2$, $-OCH_2X^{4.1}$, substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted aryl or substituted or unsubstituted heteroaryl, or when X^2 is CR^9 , then R^4 and R^9 may optionally be joined to form a substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl;

~~R^5 is independently halogen, oxo, $-CX^{5.1}_3$, $-CHX^{5.1}_2$, $-CH_2X^{5.1}$, $-CN$, $-N_3$, $-SO_{n5}R^{5A}$, $-SO_{v5}NR^{5B}R^{5C}$, $-NHN R^{5B}R^{5C}$, $-ONR^{5B}R^{5C}$, $-NHC(O)NHN R^{5B}R^{5C}$, $-NHC(O)NR^{5B}R^{5C}$, $-N(O)_{m5}$, $-NR^{5B}R^{5C}$, $-C(O)R^{5D}$, $-C(O)OR^{5D}$, $-C(O)NR^{5B}R^{5C}$, $-OR^{5A}$, $-NR^{5B}SO_2R^{5A}$, $-NR^{5B}C(O)R^{5D}$, $-NR^{5B}C(O)OR^{5D}$, $-NR^{5B}OR^{5D}$, $-OCX^{5.1}_3$, $-OCHX^{5.1}_2$, $-OCH_2X^{5.1}$, substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted aryl or substituted or unsubstituted heteroaryl;~~

~~R^6 is independently halogen, oxo, $-CX^{6.1}_3$, $-CHX^{6.1}_2$, $-CH_2X^{6.1}$, $-CN$, $-N_3$, $-SO_{n6}R^{6A}$, $-SO_{v6}NR^{6B}R^{6C}$, $-NHN R^{6B}R^{6C}$, $-ONR^{6B}R^{6C}$, $-NHC(O)NHN R^{6B}R^{6C}$,~~

~~—NHC(O)NR^{6B}R^{6C}, —N(O)_{m6}, —NR^{6B}R^{6C}, —C(O)R^{6D}, —C(O)OR^{6D}, —C(O)NR^{6B}R^{6C}, —OR^{6A}, —NR^{6B}SO₂R^{6A}, —NR^{6B}C(O)R^{6D}, —NR^{6B}C(O)OR^{6D}, —NR^{6B}OR^{6D}, —OCX^{6.1}₃, —OCHX^{6.1}₂, —OCH₂X^{6.1}, substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted aryl or substituted or unsubstituted heteroaryl;~~

R⁷ is hydrogen, halogen, —CX^{7.1}₃, —CHX^{7.1}₂, —CH₂X^{7.1}, —CN, —N₃, —SO_{n7}R^{7A}, —SO_{v7}NR^{7B}R^{7C}, —NHNR^{7B}R^{7C}, —ONR^{7B}R^{7C}, —NHC(O)NHNR^{7B}R^{7C}, —NHC(O)NR^{7B}R^{7C}, —N(O)_{m7}, —NR^{7B}R^{7C}, —C(O)R^{7D}, —C(O)OR^{7D}, —C(O)NR^{7B}R^{7C}, —OR^{7A}, —NR^{7B}SO₂R^{7A}, —NR^{7B}C(O)R^{7D}, —NR^{7B}C(O)OR^{7D}, —NR^{7B}OR^{7D}, —OCX^{7.1}₃, —OCHX^{7.1}₂, —OCH₂X^{7.1}, substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted aryl or substituted or unsubstituted heteroaryl;

~~R⁸ is hydrogen, halogen, —CX^{8.1}₃, —CHX^{8.1}₂, —CH₂X^{8.1}, —CN, —N₃, —SO_{n8}R^{8A}, —SO_{v8}NR^{8B}R^{8C}, —NHNR^{8B}R^{8C}, —ONR^{8B}R^{8C}, —NHC(O)NHNR^{8B}R^{8C}, —NHC(O)NR^{8B}R^{8C}, —N(O)_{m8}, —NR^{8B}R^{8C}, —C(O)R^{8D}, —C(O)OR^{8D}, —C(O)NR^{8B}R^{8C}, —OR^{8A}, —NR^{8B}SO₂R^{8A}, —NR^{8B}C(O)R^{8D}, —NR^{8B}C(O)OR^{8D}, —NR^{8B}OR^{8D}, —OCX^{8.1}₃, —OCHX^{8.1}₂, —OCH₂X^{8.1}, substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl;~~

R⁹ is hydrogen, halogen, —CX^{9.1}₃, —CHX^{9.1}₂, —CH₂X^{9.1}, —CN, —N₃, —SO_{n9}R^{9A}, —SO_{v9}NR^{9B}R^{9C}, —NHNR^{9B}R^{9C}, —ONR^{9B}R^{9C}, —NHC(O)NHNR^{9B}R^{9C}, —NHC(O)NR^{9B}R^{9C}, —N(O)_{m9}, —NR^{9B}R^{9C}, —C(O)R^{9D}, —C(O)OR^{9D}, —C(O)NR^{9B}R^{9C}, —OR^{9A}, —NR^{9B}SO₂R^{9A}, —NR^{9B}C(O)R^{9D}, —NR^{9B}C(O)OR^{9D}, —NR^{9B}OR^{9D}, —OCX^{9.1}₃, —OCHX^{9.1}₂, —OCH₂X^{9.1}, substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl, or when X² is CR⁹, then R⁴ and R⁹ may optionally be joined to form a substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl; or when X² is CR⁹ and X³ is CR¹⁰, then R⁹ and R¹⁰ may optionally be joined to form a substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl;

R¹⁰ is hydrogen, halogen, —CX^{10.1}₃, —CHX^{10.1}₂, —CH₂X^{10.1}, or —CN, —N₃, —SO_{n10}R^{10A}, —SO_{v10}NR^{10B}R^{10C}, —NHNR^{10B}R^{10C}, —ONR^{10B}R^{10C}, —NHC(O)NHNR^{10B}R^{10C}, —NHC(O)NR^{10B}R^{10C}, —N(O)_{m10}, —NR^{10B}R^{10C}, —C(O)R^{10D}, —C(O)OR^{10D}, —C(O)NR^{10B}R^{10C}, —OR^{10A}, —NR^{10B}SO₂R^{10A}, —NR^{10B}C(O)R^{10D}, —NR^{10B}C(O)OR^{10D}, —NR^{10B}OR^{10D}, —OCX^{10.1}₃, —

OCHX^{10.1}₂, -OCH₂X^{10.1}, substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl; or when X² is CR⁹ and X³ is CR¹⁰, then R⁹ and R¹⁰ may optionally be joined to form a substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl;

R⁴⁴ is hydrogen, -CX^{44.1}₃, -CHX^{44.1}₂, -CH₂X^{44.1}, -SO_{n44}R^{44A}, -SO_{v44}NR^{44B}R^{44C}, -C(O)R^{44D}, -C(O)OR^{44D}, -C(O)NR^{44B}R^{44C}, substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted C₃-C₈ cycloalkyl, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted aryl or substituted or unsubstituted heteroaryl;

R^{1A}, R^{1B}, R^{1C}, R^{1D}, R^{2A}, R^{2B}, R^{2C}, R^{2D}, R^{3A}, R^{3B}, R^{3C}, R^{3D}, R^{4A}, R^{4B}, R^{4C}, R^{4D}, R^{5A}, R^{5B}, R^{5C}, R^{5D}, R^{6A}, R^{6B}, R^{6C}, R^{6D}, R^{7A}, R^{7B}, R^{7C}, R^{7D}, R^{7.2B}, R^{8A}, R^{8B}, R^{8C}, R^{8D}, R^{9A}, R^{9B}, R^{9C}, R^{9D}, R^{10A}, R^{10B}, R^{10C}, R^{10D}, R^{44A}, R^{44B}, R^{44C}, and R^{44D} are independently hydrogen, halogen, -CF₃, -CCl₃, -CBr₃, -Cl₃, -COOH, -CONH₂, substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl; R^{1B}, R^{1C}, R^{2B}, R^{2C}, R^{3B}, R^{3C}, R^{4B}, R^{4C}, R^{5B}, R^{5C}, R^{6B}, R^{6C}, R^{7B}, R^{7C}, R^{8B}, R^{8C}, R^{9B}, R^{9C}, R^{10B}, R^{10C}, R^{44B}, and R^{44C} substituents bonded to the same nitrogen atom may optionally be joined to form a substituted or unsubstituted heterocycloalkyl or substituted or unsubstituted heteroaryl; and

X^{1.1}, X^{2.1}, X^{3.1}, X^{4.1}, X^{5.1}, X^{6.1}, X^{7.1}, X^{8.1}, X^{9.1}, X^{10.1}, and X^{44.1} are independently -Cl, -Br, -I or -F;


wherein at least one of X¹, X² and X³ is N.

~~2. The compound of claim 1, or a pharmaceutically acceptable salt thereof, wherein z2 is 0.~~

~~32.~~ The compound of claim 1, or a pharmaceutically acceptable salt thereof, wherein z4 is 1.

~~4. The compound of claim 1, or a pharmaceutically acceptable salt thereof, wherein z1 is 2.~~

~~5. The compound of claim 1, or a pharmaceutically acceptable salt thereof, wherein the compound has structural Formula (II):~~



(II); wherein

R^4 is hydrogen, $CX^{4.1}_{3-}$, CN , $C(O)NR^{4B}R^{4C}$, substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl;

$R^{3.2}$ is hydrogen, halogen, $CX^{3.2}_{3-}$, $CHX^{3.2}_{2-}$, $CH_2X^{3.2}_{2-}$, CN , N_3 , $SO_{n3.2}R^{3.2A}$, $SO_{v3.2}NR^{3.2B}R^{3.2C}$, $NHNR^{3.2B}R^{3.2C}$, $ONR^{3.2B}R^{3.2C}$, $NHC(O)NHNR^{3.2B}R^{3.2C}$, $NHC(O)NR^{3.2B}R^{3.2C}$, $N(O)_{m3.2}NR^{3.2B}R^{3.2C}$, $C(O)R^{3.2D}$, $C(O)OR^{3.2D}$, $C(O)NR^{3.2B}R^{3.2C}$, $OR^{3.2A}$, $NR^{3.2B}SO_2R^{3.2A}$, $NR^{3.2B}C(O)R^{3.2D}$, $NR^{3.2B}C(O)OR^{3.2D}$, $NR^{3.2B}OR^{3.2D}$, $OCX^{3.2}_{3-}$, $OCHX^{3.2}_{2-}$, $OCH_2X^{3.2}_{2-}$, substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl;

$R^{3.3}$ is hydrogen, halogen, $CX^{3.3}_{3-}$, $CHX^{3.3}_{2-}$, $CH_2X^{3.3}_{2-}$, CN , N_3 , $SO_{n3.3}R^{3.3A}$, $SO_{v3.3}NR^{3.3B}R^{3.3C}$, $NHNR^{3.3B}R^{3.3C}$, $ONR^{3.3B}R^{3.3C}$, $NHC(O)NHNR^{3.3B}R^{3.3C}$, $NHC(O)NR^{3.3B}R^{3.3C}$, $N(O)_{m3.3}NR^{3.3B}R^{3.3C}$, $C(O)R^{3.3D}$, $C(O)OR^{3.3D}$, $C(O)NR^{3.3B}R^{3.3C}$, $OR^{3.3A}$, $NR^{3.3B}SO_2R^{3.3A}$, $NR^{3.3B}C(O)R^{3.3D}$, $NR^{3.3B}C(O)OR^{3.3D}$, $NR^{3.3B}OR^{3.3D}$, $OCX^{3.3}_{3-}$, $OCHX^{3.3}_{2-}$, $OCH_2X^{3.3}_{2-}$, substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl;





$R^{3.2A}$, $R^{3.2B}$, $R^{3.2C}$, $R^{3.2D}$, $R^{3.3A}$, $R^{3.3B}$, $R^{3.3C}$ and $R^{3.3D}$ are independently hydrogen, halogen, CF_3 , CCl_3 , CBr_3 , Cl_3 , $COOH$, $CONH_2$, substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl; $R^{3.2B}$, $R^{3.2C}$, $R^{3.3B}$ and $R^{3.3C}$ substituents bonded to the same nitrogen atom may optionally be joined to form a substituted or unsubstituted heterocycloalkyl or substituted or unsubstituted heteroaryl;

$n3.2$ and $n3.3$ are independently an integer from 0 to 4;

$m3.2$, $m3.3$, $v3.2$ and $v3.3$ are independently 1 or 2; and

$X^{3.2}$ and $X^{3.3}$ are independently Cl , Br , I or F .

63. The compound of claim **51**, or a pharmaceutically acceptable salt thereof, wherein the compound has one of structural Formula (IIb), (IIc), (IIa), or (IIc):



74. The compound of claim 1, or a pharmaceutically acceptable salt thereof, wherein

X² is CR⁹;


X³ is CR¹⁰; and

R^9 is hydrogen, $-CX^{9.1}_3$, $-CHX^{9.1}_2$, $-CH_2X^{9.1}$, $-CN$, or substituted or unsubstituted C_1 - C_4 alkyl, optionally wherein R^9 is hydrogen, $-CF_3$, or unsubstituted methyl;
and


R^{10} is hydrogen, $-CX^{10.1}_3$, $-CHX^{10.1}_2$, $-CH_2X^{10.1}$, $-CN$, or substituted or unsubstituted alkyl, optionally wherein R^{10} is hydrogen or $-CN$.

~~8. The compound of claim 7, or a pharmaceutically acceptable salt thereof, wherein R^9 is hydrogen, $-CF_3$, or unsubstituted methyl.~~

~~9. The compound of claim 6, or a pharmaceutically acceptable salt thereof, wherein the compound has structural Formula (IIc):~~



~~10. The compound of claim 5, or a pharmaceutically acceptable salt thereof, wherein the compound has structural Formula (IIa):~~




~~11. The compound of claim 1, or a pharmaceutically acceptable salt thereof, wherein~~

~~X^3 is CR^{10} ; and~~

~~R^{10} is hydrogen, $-CX^{10.1}_3$, $-CHX^{10.1}_2$, $-CH_2X^{10.1}$, $-CN$, or substituted or unsubstituted C_1 - C_4 alkyl.~~

~~12. The compound of claim 11, or a pharmaceutically acceptable salt thereof, wherein R^{10} is hydrogen or $-CN$.~~

~~13.~~ The compound of claim 10, or a pharmaceutically acceptable salt thereof, wherein the compound has structural Formula (IIc):



~~514.~~ The compound of claim 1, or a pharmaceutically acceptable salt thereof, wherein R^4 is hydrogen, halogen, $-CX^{4.1}_3$, $-CHX^{4.1}_2$, $-CH_2X^{4.1}$, $-CN$, $-NR^{4B}R^{4C}$, $-C(O)R^{4D}$, $-C(O)OR^{4D}$, $-C(O)NR^{4B}R^{4C}$, $-OR^{4A}$, $-NR^{4B}C(O)R^{4D}$, $-NR^{4B}C(O)OR^{4D}$, $-OCX^{4.1}_3$, $-OCHX^{4.1}_2$, $-OCH_2X^{4.1}$, substituted or unsubstituted alkyl, or substituted or unsubstituted heteroalkyl, optionally wherein R^4 is $-Cl$, $-Br$, $-F$, $-CN$, $-COOH$, $-C(O)OCH_2CH_3$, $-C(CH_3)_2OH$, $-C(O)NH_2$, $-CF_3$, or $-CH_3$.

~~15.~~ The compound of claim 1, or a pharmaceutically acceptable salt thereof, wherein R^4 is hydrogen, halogen, $-CX^{4.1}_3$, $-CHX^{4.1}_2$, $-CH_2X^{4.1}$, $-CN$, $-C(O)OR^{4D}$, $-C(O)NR^{4B}R^{4C}$, substituted or unsubstituted C_1 - C_4 -alkyl, or substituted or unsubstituted 2 to 4 membered heteroalkyl.

~~16.~~ The compound of claim 1, or a pharmaceutically acceptable salt thereof, wherein R^4 is $-Cl$, $-Br$, $-F$, $-CN$, $-COOH$, $-C(O)OCH_2CH_3$, $-C(CH_3)_2OH$, $-C(O)NH_2$, $-CF_3$, or $-CH_3$.

~~617.~~ The compound of claim 1, or a pharmaceutically acceptable salt thereof, wherein

X^2 is CR^9 ; and

R^4 and R^9 are joined to form a substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl, optionally wherein R^4 and R^9 are joined to form an unsubstituted cycloalkyl, unsubstituted heterocycloalkyl, unsubstituted phenyl, or unsubstituted heteroaryl, further optionally wherein R^4 and R^9 are joined to form an unsubstituted cycloalkyl, unsubstituted thienyl, or unsubstituted phenyl.

~~18. The compound of claim 17, or a pharmaceutically acceptable salt thereof, wherein R⁴ and R⁹ are joined to form a substituted or unsubstituted C₅-C₇ cycloalkyl, substituted or unsubstituted 5 to 7 membered heterocycloalkyl, substituted or unsubstituted phenyl, or substituted or unsubstituted 5 to 6 membered heteroaryl.~~

~~19. The compound of claim 17, or a pharmaceutically acceptable salt thereof, wherein R⁴ and R⁹ are joined to form an unsubstituted C₅-C₇ cycloalkyl, unsubstituted 5 to 7 membered heterocycloalkyl, unsubstituted phenyl, or unsubstituted 5 to 6 membered heteroaryl.~~

~~20. The compound of claim 17, or a pharmaceutically acceptable salt thereof, wherein R⁴ and R⁹ are joined to form an unsubstituted C₅ cycloalkyl, unsubstituted thienyl, or unsubstituted phenyl.~~

~~721.~~ The compound of claim 1, or a pharmaceutically acceptable salt thereof, wherein R⁴⁴ is hydrogen.

~~822.~~ The compound of claim 1, or a pharmaceutically acceptable salt thereof, wherein R¹ and R² are independently hydrogen, substituted or unsubstituted alkyl or substituted or unsubstituted heteroalkyl, optionally wherein one of R¹ and R² is hydrogen and the other is -CH₃.

~~23. The compound of claim 1, or a pharmaceutically acceptable salt thereof, wherein R¹ is substituted or unsubstituted alkyl.~~

~~24. The compound of claim 1, or a pharmaceutically acceptable salt thereof, wherein R¹ is -CH₃.~~

~~25. The compound of claim 1, or a pharmaceutically acceptable salt thereof, wherein R¹ is hydrogen.~~

~~26. The compound of claim 1, or a pharmaceutically acceptable salt thereof, wherein R² is substituted or unsubstituted alkyl.~~

~~27. The compound of claim 1, or a pharmaceutically acceptable salt thereof, wherein R² is -CH₃.~~

~~28. The compound of claim 1, or a pharmaceutically acceptable salt thereof, wherein R² is hydrogen.~~

~~29. The compound of claim 5, or a pharmaceutically acceptable salt thereof, wherein R^{3.2} and R^{3.3} are independently halogen.~~

~~930. The compound of claim 15, or a pharmaceutically acceptable salt thereof, wherein R^{3.2} and R^{3.3} are independently chlorine.~~

~~1031. The compound of claim 1, or a pharmaceutically acceptable salt thereof, wherein L⁷ is a bond, substituted or unsubstituted alkylene, or substituted or unsubstituted cycloalkylene, optionally wherein L⁷ is a bond, an unsubstituted cycloalkylene, a substituted or unsubstituted cyclobutylene or a substituted or unsubstituted alkylene.~~

~~32. The compound of claim 1, or a pharmaceutically acceptable salt thereof, wherein L⁷ is a substituted or unsubstituted C₄-C₆ cycloalkylene.~~

~~33. The compound of claim 1, or a pharmaceutically acceptable salt thereof, wherein L⁷ is an unsubstituted C₄-C₆ cycloalkylene.~~

~~34. The compound of claim 1, or a pharmaceutically acceptable salt thereof, wherein L⁷ is a substituted or unsubstituted cyclobutylene.~~


~~35. The compound of claim 1, or a pharmaceutically acceptable salt thereof, wherein L⁷ is a substituted or unsubstituted alkylene.~~

~~36. The compound of claim 1, or a pharmaceutically acceptable salt thereof, wherein L⁷ is a substituted or unsubstituted C₁-C₆ alkylene.~~

~~37. The compound of claim 1, or a pharmaceutically acceptable salt thereof, wherein L⁷ is a bond.~~

~~1138. The compound of claim 1, or a pharmaceutically acceptable salt thereof, wherein R⁷ is hydrogen, halogen, -SO_{n7}R^{7A}, -SO_{v7}NR^{7B}R^{7C}, -NHC(O)NR^{7B}R^{7C}, -NR^{7B}R^{7C}, -C(O)R^{7D}, -C(O)OR^{7D}, -C(O)NR^{7B}R^{7C}, -OR^{7A}, -NR^{7B}SO₂R^{7A}, -NR^{7B}C(O)R^{7D}, -NR^{7B}C(O)OR^{7D}, substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted aryl or substituted or unsubstituted heteroaryl, optionally wherein R⁷ is hydrogen, substituted or unsubstituted alkyl, substituted or unsubstituted phenyl, -C(O)OH, -C(O)OCH₃, -C(O)OCH₂CH₃, -CH₂C(O)OH, -NHC(O)OH, -NHC(O)OCH₃, -NHC(O)OCH₂CH₃, -CH₂C(O)OH, -CH₂C(O)OCH₃.~~

~~-CH₂C(O)OCH₂CH₃, -SO₂CH₃, -SO₂CH₂CH₃, -SO₂CH(CH₃)₂, -NHSO₂CH₃, -NHSO₂CH₂CH₃,
-NHSO₂CH(CH₃)₂, -SO₂NH₂, -SO₂NHCH₃, -(CH₂)₂OH, -CH₂C(CH₃)₂OH, -(CH₂)₃OH,
-(CH₂)₂CH(CH₃)₂OH, -(CH₂)₂SO₂NH₂, -(CH₂)₃SO₂NH₂, -(CH₂)₂CONH₂, -(CH₂)₃CONH₂,
-(CH₂)₃CON(H)Me, -(CH₂)₃CON(Me)₂, -(CH₂)₂SO₂Me, -(CH₂)₃SO₂Me, -CH₂CH(OH)Me,
-CH₂CO₂H, -(CH₂)₂CO₂H, -CH(CH₃)CH₂CO₂H, -(CH₂)₃CO₂H, -(CH₂)₂SO₂NHCH₃,
-(CH₂)₂SO₂N(CH₃)₂, -(CH₂)₂SO₂-(N-morpholinyl), -(CH₂)₂NHCOCH₃, -(CH₂)₃NHCOCH₃,
-(CH₂)₂NHCOCH(CH₃)₂, -(CH₂)₂NHSO₂CH₃, -(CH₂)₂NHSO₂CF₃, -(CH₂)₂NHSO₂NHCH(CH₃)₂,
-CH₂CH(CH₃)CH₂OH (R and S), -CH(CH₃)(CH₂)₂OH, -CH₂-(2-imidazolyl), -CH₂-(4-imidazolyl),
-CH₂-(3-pyrazolyl), 4-tetrahydropyranyl, 3-oxetanyl, -(CH₂)₂NHCO₂Me, -(CH₂)₃NHCO₂Me,~~




39. ~~The compound of claim 1, or a pharmaceutically acceptable salt thereof, wherein R⁷ is OR^{7A}, C(O)R^{7D}, C(O)OR^{7D}, C(O)NR^{7B}R^{7C}, SO_{n7}R^{7A}, SO_{n7}NR^{7B}R^{7C}, substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted aryl or substituted or unsubstituted heteroaryl.~~


40. ~~The compound of claim 1, or a pharmaceutically acceptable salt thereof, wherein R⁷ is hydrogen, substituted or unsubstituted alkyl, substituted or unsubstituted phenyl, C(O)OH, C(O)OCH₃, C(O)OCH₂CH₃, CH₂C(O)OH, NHC(O)OH, NHC(O)OCH₃, NHC(O)OCH₂CH₃, CH₂C(O)OH, CH₂C(O)OCH₃, CH₂C(O)OCH₂CH₃, SO₂CH₃, SO₂CH₂CH₃, SO₂CH(CH₃)₂, NHSO₂CH₃, NHSO₂CH₂CH₃, NHSO₂CH(CH₃)₂, SO₂NH₂, SO₂NHCH₃, F, OH, CH₂OH, (CH₂)₂OH, (CH₂)₃OH, C(CH₃)₂OH, CH₂SO₂NH₂, (CH₂)₂SO₂NH₂, CH₂C(O)NH₂, (CH₂)₂C(O)NH₂, (CH₂)₃C(O)NH₂, CH₂NHSO₂CF₃, (CH₂)₂NHSO₂CF₃, (CH₂)₃NHSO₂CF₃, CH₂NHSO₂CH₃, (CH₂)₂NHSO₂CH₃, (CH₂)₃NHSO₂CH₃, CH₂SO₂CH₃, (CH₂)₂SO₂CH₃, CH₂SO₂NH₂, or (CH₂)₂SO₂NH₂.~~

41. ~~The compound of claim 1, or a pharmaceutically acceptable salt thereof, wherein R⁷ is hydrogen, substituted or unsubstituted alkyl, substituted or unsubstituted phenyl, C(O)OH, C(O)OCH₃, C(O)OCH₂CH₃, CH₂C(O)OH, NHC(O)OH, NHC(O)OCH₃, NHC(O)OCH₂CH₃, CH₂C(O)OH, CH₂C(O)OCH₃, CH₂C(O)OCH₂CH₃,~~

~~SO₂CH₃, SO₂CH₂CH₃, SO₂CH(CH₃)₂, NHSO₂CH₃, NHSO₂CH₂CH₃, NHSO₂CH(CH₃)₂, SO₂NH₂, SO₂NHCH₃, (CH₂)₂OH, CH₂C(CH₃)₂OH, (CH₂)₃OH, (CH₂)₂CH(CH₃)₂OH, (CH₂)₂SO₂NH₂, (CH₂)₃SO₂NH₂, (CH₂)₂CONH₂, (CH₂)₃CONH₂, (CH₂)₃CON(H)Me, (CH₂)₃CON(Me)₂, (CH₂)₂SO₂Me, (CH₂)₃SO₂Me, CH₂CH(OH)Me, CH₂CO₂H, (CH₂)₂CO₂H, CH(CH₃)CH₂CO₂H, (CH₂)₃CO₂H, (CH₂)₂SO₂NHCH₃, (CH₂)₂SO₂N(CH₃)₂, (CH₂)₂SO₂(N-morpholinyl), (CH₂)₂NHCOCH₃, (CH₂)₃NHCOCH₃, (CH₂)₂NHCOCH(CH₃)₂, (CH₂)₂NHSO₂CH₃, (CH₂)₂NHSO₂CF₃, (CH₂)₂NHSO₂NHCH(CH₃)₂, CH₂CH(CH₃)CH₂OH (R and S), CH(CH₃)(CH₂)₂OH, CH₂-(2-imidazolyl), CH₂-(4-imidazolyl), CH₂-(3-pyrazoyl), 4-~~





~~tetrahydropyranyl, 3-oxetanyl, (CH₂)₂NHCO₂Me, (CH₂)₃NHCO₂Me, CH₂OH,~~





1242. The compound of claim 1, or a pharmaceutically acceptable salt thereof, wherein -L⁷-R⁷ is carboxylic acid substituted cyclobutyl, carboxylic acid substituted cyclopentyl, or hydroxyl substituted ethyl; all optionally further substituted with substituted or unsubstituted alkyl.

1343. The compound of claim 1, or a pharmaceutically acceptable salt thereof, wherein the compound has the structure:













14. The compound of claim 1, or a pharmaceutically acceptable salt thereof, wherein the compounds has the structure:



or




15. The compound of claim 1, or a pharmaceutically acceptable salt thereof, wherein the compound has the structure:




or


16. The compound of claim 1, or a pharmaceutically acceptable salt thereof, wherein the compound has the structure:




or




17. The compound of claim 1, or a pharmaceutically acceptable salt thereof, wherein the compound has the structure:




or




18. The compound of claim 1, or a pharmaceutically acceptable salt thereof, wherein the compound has the structure:




or



19. The compound of claim 1, or a pharmaceutically acceptable salt thereof, wherein the compound has the structure:



or



2044. A pharmaceutical composition comprising a pharmaceutically acceptable excipient and a compound of any one of claim 1 to 19, or a pharmaceutically acceptable salt thereof.

2145. ~~A method of~~ The compound of any one of claims 1 to 19 for use as a medicament for treating or preventing a disease or disorder mediated by CCR4, ~~comprising administering to a subject in need thereof a therapeutically effective amount of a compound of claim 1, or a pharmaceutically acceptable salt thereof.~~ wherein the disease or disorder is an immune disease or disorder, inflammatory disease or disorder, cardiovascular disease or disorder, metabolic disease or disorder, or cancer.

2246. ~~A method of~~ The pharmaceutical composition of claim 20 for use as a medicament for treating or preventing a disease or disorder mediated by CCR4, ~~comprising administering to a subject in need thereof a therapeutically effective amount of the pharmaceutical composition of claim 44.~~ wherein the disease or disorder is an immune disease or disorder, inflammatory disease or disorder, cardiovascular disease or disorder, metabolic disease or disorder, or cancer.

2347. ~~A method of~~ The compound of any one of claims 1 to 19 for use as a medicament for inhibiting C-C chemokine receptor type 4 (CCR4), ~~comprising contacting CCR4 with a compound of claim 1, or a pharmaceutically acceptable salt thereof.~~

2448. ~~The method compound for use of claim-~~ 2145, wherein the disease or disorder is an immune or inflammatory disease or disorder. optionally adapted for co-administration with an anti-inflammatory agent, a cardiovascular agent, a metabolic disorder agent, a chemotherapeutic agent or anticancer agent to the subject.

wherein the anti-inflammatory agent is thalidomide or a derivative thereof, a retinoid, dithranol, calcipotriol, a non-steroidal anti-inflammatory agent (NSAID), a cyclo-oxygenase inhibiting nitric oxide donor (CINOD), a glucocorticosteroid, methotrexate, leflunomide, hydroxychloroquine, d-penicillamine, auranofin, an analgesic, a diacerein, or hyaluronic acid

derivative;

wherein the cardiovascular agent is a calcium channel blocker, a beta-adrenoceptor blocker, an angiotensin-converting enzyme (ACE) inhibitor, an angiotensin-2 receptor antagonist, a lipid lowering agent, a modulator of blood cell morphology, a thrombolytic, or an anticoagulant; and

wherein the chemotherapeutic agent or anticancer agent is an antiproliferative/antineoplastic drug, an antimetabolite, an antitumour antibiotic, an antimitotic agent, a topoisomerase inhibitor, a cytostatic agent, an oestrogen receptor down regulator, an antiandrogen, a LHRH antagonist or LHRH agonist, a progestogen, an aromatase inhibitor, an inhibitor of 5 α -reductase, an agent which inhibits cancer cell invasion, an inhibitor of growth factor function, a farnesyl transferase inhibitor, a tyrosine kinase inhibitor, a serine/threonine kinase inhibitor, an inhibitor of the epidermal growth factor family, an inhibitor of the platelet-derived growth factor family, an inhibitor of the hepatocyte growth factor family; an antiangiogenic agent, a vascular damaging agent, an agent used in antisense therapy, an anti-ras antisense, an agent used in a gene therapy, an immunotherapeutic agent, or an antibody.

~~49.—The method of claim 48, further comprising co-administering an anti-inflammatory agent to the subject.~~

~~50.—The method of claim 49, wherein the anti-inflammatory is thalidomide or a derivative thereof, a retinoid, dithranol, calcipotriol, a non-steroidal anti-inflammatory agent (NSAID), a cyclo-oxygenase inhibiting nitric oxide donor (CINOD), a glucocorticosteroid, methotrexate, leflunomide, hydroxychloroquine, D-penicillamine, auranofin, an analgesic, a diacerein, hyaluronic acid derivative, or a nutritional supplement.~~

~~51.—The method of claim 45, wherein the disease or disorder is a cardiovascular or metabolic disease or disorder.~~

~~52.—The method of claim 51, further comprising co-administering a cardiovascular agent or a metabolic disorder agent to the subject.~~

~~53.—The method of claim 52, wherein the cardiovascular agent is a calcium channel blocker, a beta-adrenoceptor blocker, an angiotensin-converting enzyme (ACE) inhibitor, an angiotensin-2 receptor antagonist, a lipid lowering agent, a modulator of blood cell morphology, a thrombolytic, or an anticoagulant.~~

~~54.—The method of claim 45, wherein the disease or disorder is cancer.~~

~~55. The method of claim 54, further comprising co-administering a chemotherapeutic agent or anticancer agent to the subject.~~

~~56. The method of claim 55, wherein the chemotherapeutic agent or anticancer agent is an antiproliferative/antineoplastic drug, an antimetabolite, an antitumour antibiotic, an antimitotic agent, a topoisomerase inhibitor, a cytostatic agent, an oestrogen receptor down regulator, an antiandrogen, a LHRH antagonist or LHRH agonist, a progestogen, an aromatase inhibitor, an inhibitor of 5 α -reductase, an agent which inhibits cancer cell invasion, an inhibitor of growth factor function, a farnesyl transferase inhibitor, a tyrosine kinase inhibitor, a serine/threonine kinase inhibitor, an inhibitor of the epidermal growth factor family, an inhibitor of the platelet-derived growth factor family, an inhibitor of the hepatocyte growth factor family; an antiangiogenic agent, a vascular damaging agent, an agent used in antisense therapy, an anti-ras antisense, an agent used in a gene therapy, an immunotherapeutic agent, or an antibody.~~

2557. The compound for use of claim 24, wherein the chemotherapeutic agent or anticancer agent is an inhibitor of the PD-L1/PD-1 pathway, an inhibitor of CTLA-4 or an agonistic antibody of CD137 (4-1BB). ~~The method of claim 56, further comprising co-administering a therapeutically effective amount of at least two of: a CCR4 inhibitor, an inhibitor of the PD-L1/PD-1 pathway, an inhibitor of CTLA-4 or an agonistic antibody of CD137 (4-1BB).~~

2658. The compound for use of claim 24 optionally adapted for co-administration with an ~~The method of claim 56, further comprising co-administering a therapeutically effective amount of at least two of: a CCR4 inhibitor, an immune modulator agent, or an agent from Table 1, wherein the immune modulator agent is~~ TSR-022, MGB453, BMS-986016, IMP321, MGA271, MGD-009, RG-6058, AMG 557, SEA-CD40, dacetuzumab, CP-870,893, Chi Lob 7/4, lucatumumab, galiximab, INCAGN1876, TRX518, MEDI-570, MEDI-6469, INCAGN1949, huMab OX40L, monalizumab, galunisertib, luspatercept, YH-14618, dalantercept, BG-00011, trabedersen, isth-0036, ace-083, NKTR-214, recombinant IL2, aldesleukin, EGEN-001, NHS-IL12, recombinant IL-7, NIZ-985, ALT-803, recombinant IL-21, anti-CD20, IL21, talokinumab, dupilumab, cabiralizumab, INCB50465, idealisib, TGR-1202, AMG319, IPI-549, azacytidine, decitabine, guadecitabine, vorinostat, panobinostat, belinostat, entinostat, mocetinostat, givinostat, chidamide, quisinostat, abexinostat, chr-3996, ar-42, INCN54329, INCB57643, birabresib, apabetalone, alvocidib, PLX-51107, FT-1101, RG-6146, AZD-8186, CPI-0610, JQ1, INCB59872, IMG-

7289, RG-6016, CC-90011, GSK-2879552, ORY-2001, 4SC-202, ORY-3001, recombinant TNFa, MEDI-1873, FPA-154, LKZ-145, recombinant IL1, recombinant interferon alpha-n1, recombinant interferon alpha-2b, recombinant interferon alpha-n3, recombinant IFN beta-1a, actimmune, cyclic di-nucleotides, poly I:C, IMO-2055, TMX-101, imiquimod, CpG, MGN1703, glucopyranosyl lipid A, CBLB502, BCG, HILTONOL, AMPLIGEN, MOTOLIMOD, DUK-CPG-001, AS15, recombinant IL-10, CCX140, CCX872, BMS-813160, CENICRIVIROC, CNTX-6970, PF-4136309, plozalizumab, INCB-9471, PF-04634817, maraviroc, PRO-140, BMS-813160, NIFEVIROC, OHR-118, ulocuplumab, plerixafor, x4p-001, usl-311, ly-2510924, APH-0812, BL-8040, BURIXAFOR, BALIXAFORTIDE, PTX-9908, GMI-1359, F-50067, IPH-4301, CA-170, ISTRADEFYLLINE, TOZADENANT, PBF-509, PBF-999, CPI-444, OREG-103, anti-CD39 antibodies, oleclumab, PBF-1662, anti-CD73 antibodies, pembrolizumab, nivolumab, INCSHR1210, CT-011, AMP224, atezolizumab, avelumab, tremelimumab, urelumab, utomilumab, BMS-663513, PF-05082566, BGB-324, BPI-9016M, S-49076, ibrutinib, Cb-1158, MDX-1140, AMP-110, PT2385, CDX-301, FLX925, quizartinib, gilteritinib, PKC412, midostaurin, crenolanib, lirlumab, IPH-2101, anti-CD47, TTI-621, NI-1701, SRF-231, Effi-DEM, RCT-1938, epacadostat, F287, BMS983205, GDC-0919, or indoximod, or any combination thereof.

2759. The compound for use~~method~~ of claim 2154, wherein the cancer is colon cancer or pancreatic cancer.


28.60. The compound for use~~method~~ of claim 2145, wherein the disease or disorder is allergy-related.

2961. The compound for use~~method~~ of claim 2145, wherein the disease or disorder is inflammation, wherein the inflammation is asthma, urticaria, rhinitis, or dermatitis.

~~62.——The method of claim 45, wherein the disease or disorder is asthma or dermatitis.~~

3063. The ~~method~~compound for use of claim 2962, wherein the ~~inflammation disease or disorder~~ is allergic asthma, autoimmune urticaria, allergic rhinitis or contact dermatitis.


~~64.——A compound having the formula:~~



thereof.

, or a pharmaceutically acceptable salt


65. A compound having the formula:



thereof.

, or a pharmaceutically acceptable salt


66. A compound having the formula:



thereof.

, or a pharmaceutically acceptable salt


67. A compound having the formula:



salt thereof.

, or a pharmaceutically acceptable


68. — A compound having the formula:



thereof.

, or a pharmaceutically acceptable salt

69. — A compound having the formula:



thereof.

, or a pharmaceutically acceptable salt

70. — A compound having the formula:




~~71. A compound having the formula:~~



~~72. A compound having the formula:~~




~~73. A compound having the formula:~~



salt thereof.

_____, or a pharmaceutically acceptable


74. _____ A compound having the formula:



thereof.

_____, or a pharmaceutically acceptable salt

75. _____ A compound having the formula:



thereof.

_____, or a pharmaceutically acceptable salt